These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24784785)

  • 41. Drug & alcohol testing. Oral fluid testing update.
    Andrie M
    Occup Health Saf; 2001 Aug; 70(8):32-4. PubMed ID: 11523283
    [No Abstract]   [Full Text] [Related]  

  • 42. The controversy over urine drug testing in pain management patient monitoring.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):320-1. PubMed ID: 24303832
    [No Abstract]   [Full Text] [Related]  

  • 43. Testing is 'the technology of addiction'.
    Enos G
    Behav Healthc; 2014; 34(2):43. PubMed ID: 24864551
    [No Abstract]   [Full Text] [Related]  

  • 44. Commentary.
    Broussard LA
    Clin Chem; 2009 Oct; 55(10):1768. PubMed ID: 19786587
    [No Abstract]   [Full Text] [Related]  

  • 45. Treating pain in patients with drug-dependence problems.
    Ballantyne JC
    BMJ; 2013 Dec; 347():f3213. PubMed ID: 24324214
    [No Abstract]   [Full Text] [Related]  

  • 46. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Advantages and limitations of Triage DOA screening in clinical and forensic drug testing].
    Moriya F
    Chudoku Kenkyu; 2008 Jul; 21(3):273-83. PubMed ID: 18712071
    [No Abstract]   [Full Text] [Related]  

  • 48. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.
    Knisely JS; Wunsch MJ; Cropsey KL; Campbell ED
    J Subst Abuse Treat; 2008 Dec; 35(4):380-6. PubMed ID: 18657935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physical examination of substance abusers. How to gather evidence of concealed problems.
    Westreich LM; Rosenthal RN
    Postgrad Med; 1995 Apr; 97(4):111-2, 117-20, 123. PubMed ID: 7716085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does adherence monitoring reduce controlled substance abuse in chronic pain patients?
    Manchikanti L; Manchukonda R; Damron KS; Brandon D; McManus CD; Cash K
    Pain Physician; 2006 Jan; 9(1):57-60. PubMed ID: 16700282
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addiction disorders.
    Merrill JO; Duncan MH
    Med Clin North Am; 2014 Sep; 98(5):1097-122. PubMed ID: 25134875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Legal measures in illicit drug detection: A study on the doctor's duty in confidentiality and notice of patients information].
    Hashimoto Y
    Chudoku Kenkyu; 2011 Sep; 24(3):189-92. PubMed ID: 21950016
    [No Abstract]   [Full Text] [Related]  

  • 53. Screening for Drug Use in Primary Care: Practical Implications of the New USPSTF Recommendation.
    Bradley KA; Lapham GT; Lee AK
    JAMA Intern Med; 2020 Aug; 180(8):1050-1051. PubMed ID: 32515790
    [No Abstract]   [Full Text] [Related]  

  • 54. Role of drug testing as an early warning programme: the experience of the Republic of Korea.
    Chung H
    Bull Narc; 2005; 57(1-2):231-48. PubMed ID: 21338024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Public policy statement on drug testing as a component of addiction treatment and monitoring programs and in other clinical settings.
    J Addict Dis; 2003; 22(3):114-9. PubMed ID: 14621351
    [No Abstract]   [Full Text] [Related]  

  • 56. Abstinence-based incentives in methadone maintenance: interaction with intake stimulant test results.
    Stitzer ML; Peirce J; Petry NM; Kirby K; Roll J; Krasnansky J; Cohen A; Blaine J; Vandrey R; Kolodner K; Li R
    Exp Clin Psychopharmacol; 2007 Aug; 15(4):344-50. PubMed ID: 17696681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Roadside drug testing: unanswered questions and future challenges.
    Lenné MG
    Drug Alcohol Rev; 2007 Mar; 26(2):107-8. PubMed ID: 17364844
    [No Abstract]   [Full Text] [Related]  

  • 58. Dextropropoxyphene dependence: a cautionary note.
    Edwin T; Nammalvar N; Ramanujam V
    J Assoc Physicians India; 2001 May; 49():571-3. PubMed ID: 11361277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Demystifying analytical approaches for urine drug testing to evaluate medication adherence in chronic pain management.
    McMillin GA; Slawson MH; Marin SJ; Johnson-Davis KL
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):322-39. PubMed ID: 24147959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):124-31. PubMed ID: 22104461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.